6 results
The primary objective of the study is to evaluate the long-term safety of reslizumab at a dosage of 3.0 mg/kg every 4 weeks for approximately 24 months in pediatric and adult patients with eosinophilic asthma as assessed. The secondary objectives of…
The primary objective of this study is to determine the ability of reslizumab (110 mg) administered subcutaneously (sc) once every 4 weeks to produce a corticosteroid-sparing effect (as demonstrated by percent reduction in daily OCS use) in patients…
The primary objective of this study is to determine whether reslizumab, at a dosage of 0.3 or 3.0 mg/kg administered once every 4 weeks for a total of 4 doses, is more effective than placebo in improving lung function in patients with eosinophilic…
Assess cognitive efficacy of gantenerumab, solanezumab in individuals who have mutations causing dominantly inherited Alzheimer's disease as measured by change in the DIAN-TU cognitive composite score between baseline and a minimum of 4 years.…
The primary objective is to determine the limited-efficacy of both the experimental systems in comparison to our previous cohort that was treated with the more traditional MCGR. Limited-efficacy will be determined in terms of maintenance of the…
Primary objectiveDemonstrate that the SENSA Bladder Sensor can detect the bladder before urination among its adult intended user Secondary objective(s)1) Collect real-life data to evaluate the clinical performance of the SENSA Bladder Sensor, the…